{"id":"fluspirilene","rwe":[],"tags":[{"label":"fluspirilene","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"DRD4","category":"gene"},{"label":"N05AG01","category":"atc"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"redeptin","offLabel":[],"synonyms":["fluspirilene","fluspirilen","fluspiriline","redeptin","R 6218","R-6218"],"timeline":[],"approvals":[],"brandName":"Redeptin","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"D(2) dopamine receptor","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"OPRL1","source":"DrugCentral","target":"Nociceptin receptor","protein":"Nociceptin receptor"}],"modality":"Small Molecule","drugClass":"fluspirilene","explanation":"Think of dopamine as a messenger that helps control movement and emotions. When Redeptin blocks dopamine receptors, it helps reduce the abnormal activity in the brain that can cause symptoms of schizophrenia. This can help people with schizophrenia feel more balanced and in control.","oneSentence":"Redeptin works by blocking dopamine receptors in the brain.","technicalDetail":"Redeptin acts as a selective antagonist at the D(2) dopamine receptor subtype, which is thought to be involved in the pathophysiology of schizophrenia."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1222","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUSPIRILENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUSPIRILENE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:36:40.597472","biosimilars":[],"competitors":[{"drugName":"pimozide","drugSlug":"pimozide","fdaApproval":"1984-07-31","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"fluspirilene","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pimozide","brandName":"pimozide","genericName":"pimozide","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05960045","phase":"NA","title":"Testing Tolerance in Cow Milk Protein Allergy Patients: Milk Ladder or Direct Milk Administration?","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-07-01","conditions":["Cow Milk Allergy","Tolerance"],"enrollment":116,"completionDate":"2025-04-28"},{"nctId":"NCT03001128","phase":"","title":"Biomarkers to Predict Time to Plasma HIV RNA Rebound","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-02-23","conditions":["HIV-1 Infection"],"enrollment":61,"completionDate":"2021-01-29"},{"nctId":"NCT04752241","phase":"NA","title":"Preservation of Inferior Mesenteric Artery Could Improve Sexual Function After Laparoscopic Colorectal Resection for Diverticular Disease","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-01-01","conditions":["Sexual Function Disturbances"],"enrollment":300,"completionDate":"2024-01-01"},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":["Diabetes Mellitus, Type 1","Type 1 Diabetes","Postprandial Hyperglycemia"],"enrollment":26,"completionDate":"2024-04"},{"nctId":"NCT04190251","phase":"NA","title":"PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2016-04-14","conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic"],"enrollment":73,"completionDate":"2022-12-20"},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":["Type 1 Diabetes","Type 1 Diabetes Mellitus","Hyperglycemia, Postprandial"],"enrollment":36,"completionDate":"2022-01-30"},{"nctId":"NCT02744976","phase":"PHASE4","title":"Coronary Artery Disease Progression in Patients With Prediabetes","status":"COMPLETED","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2016-02","conditions":["Coronary Artery Disease","Atherosclerosis","Prediabetic State"],"enrollment":70,"completionDate":"2021-09"},{"nctId":"NCT04797533","phase":"NA","title":"Minebea: Inpatient Monitoring Activity Project (IMAP) (Pilot)","status":"TERMINATED","sponsor":"Surrey and Borders Partnership NHS Foundation Trust","startDate":"2019-06-14","conditions":["Psychiatric Disorder"],"enrollment":18,"completionDate":"2020-10-15"},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":["Schizophrenia"],"enrollment":174,"completionDate":"2020-08"},{"nctId":"NCT03641898","phase":"","title":"Intravascular Ultrasound-derived Assessment of Hemodynamically Negative Lesions in NSTEACS Patients","status":"UNKNOWN","sponsor":"Tianjin Chest Hospital","startDate":"2018-10-20","conditions":["Non-ST-segment Acute Coronary Syndrome"],"enrollment":350,"completionDate":"2025-10"},{"nctId":"NCT03581968","phase":"NA","title":"Efficacy of Closed-Loop Strategy With and Without a Learning Component in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp","status":"COMPLETED","sponsor":"McGill University","startDate":"2018-07-02","conditions":["Diabetes","Type 1 Diabetes Mellitus"],"enrollment":45,"completionDate":"2018-08-10"},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":["Schizophrenia","Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders"],"enrollment":21,"completionDate":"2016-06-22"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT01437553","phase":"NA","title":"Imaging Whole Coronary Artery With Intravascular Ultrasound (Ivus) And Imap For Plaque Tissue Composition In Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2011-08","conditions":["Acute Coronary Syndrome"],"enrollment":100,"completionDate":"2013-03"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"},{"nctId":"NCT01505049","phase":"","title":"Immune Memory After Papillomavirus Vaccination","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-01","conditions":["Healthy Volunteers"],"enrollment":203,"completionDate":"2015-01"},{"nctId":"NCT00119509","phase":"PHASE3","title":"The IMAP Study Improving Management of Mildly Abnormal Pap Smears","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2004-01","conditions":["Cervix Neoplasms"],"enrollment":300,"completionDate":"2008-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167366","NDDF":"003485","UNII":"C5QA4GLR9M","CHEBI":"CHEBI:93369","INN_ID":"1801","RXNORM":"4507","UMLSCUI":"C0016383","ChEMBL_ID":"CHEMBL46516","KEGG_DRUG":"D02629","DRUGBANK_ID":"DB04842","PUBCHEM_CID":"3396","SNOMEDCT_US":"321692003","IUPHAR_LIGAND_ID":"85","MESH_DESCRIPTOR_UI":"D005484"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":165,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AG01","allCodes":["N05AG01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Redeptin (FLUSPIRILENE) is a small molecule fluspirilene drug that targets the D(2) dopamine receptor. It is used to treat schizophrenia, but its commercial status and regulatory approval are unknown. As a dopamine antagonist, Redeptin works by blocking the action of dopamine in the brain, which is thought to help alleviate symptoms of schizophrenia. The exact pharmacokinetic properties of Redeptin, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}